Monopar Therapeutics Income Statement
MNPR|6 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Monopar Therapeutics reported $0 in revenue and $14M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $6.8M | $3.2M | $2.9M | $2.4M | $1.2M | $912.5K |
| R&D Expense | $9.9M | $5.6M | $7.6M | $2.0M | $935.3K | $280.4K |
| Operating Income | -$16.7M | -$8.8M | -$10.5M | -$4.3M | -$16.6M | -$1.2M |
| Interest Expense | - | - | $21.2K | - | $48.3K | $7.2K |
| Income Tax | $800 | $800 | $800 | $0 | -$3.6K | $800 |
| Net Income | -$13.7M | -$8.4M | -$10.5M | -$4.2M | -$16.6M | -$1.2M |
| EPS (Basic) | -$4.11 | -$3.04 | -$0.83 | - | - | - |
| EPS (Diluted) | - | - | - | -$0.35 | -$1.89 | -$1.89 |
| Shares Outstanding | 6.1M | 3.0M | 12.9M | 9.3M | 9.3M | 0 |